Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Accumulated Expenses: 2009-2024

Historic Accumulated Expenses for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to $55.3 million.

  • Cytokinetics' Accumulated Expenses rose 23.70% to $61.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.6 million, marking a year-over-year increase of 23.70%. This contributed to the annual value of $55.3 million for FY2024, which is 29.74% up from last year.
  • According to the latest figures from FY2024, Cytokinetics' Accumulated Expenses is $55.3 million, which was up 29.74% from $42.6 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Accumulated Expenses ranged from a high of $55.3 million in FY2024 and a low of $19.3 million during FY2020.
  • Its 3-year average for Accumulated Expenses is $47.4 million, with a median of $44.1 million in 2022.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 77.94% in 2021, then declined by 3.30% in 2023.
  • Cytokinetics' Accumulated Expenses (Yearly) stood at $19.3 million in 2020, then skyrocketed by 77.94% to $34.4 million in 2021, then increased by 28.30% to $44.1 million in 2022, then fell by 3.30% to $42.6 million in 2023, then rose by 29.74% to $55.3 million in 2024.